Atossa Therapeutics, Inc. (ATOS)

In February 2026, Atossa reaffirmed its market position for (Z)-endoxifen in Duchenne Muscular Dystrophy following the reauthorization of the Rare Pediatric Disease Priority Review Voucher Program. In December 2025, Atossa received the Clinical Trials Arena Excellence Award and shares rose after the FDA granted Rare Pediatric Disease designation to (Z)-Endoxifen for Duchenne Muscular Dystrophy. In November 2025, the company announced its Q3 2025 financial results, reporting a net loss of $8.7 million and progress in its (Z)-endoxifen development strategy. In August 2025, Atossa announced its Q2 2025 financial results and received positive feedback from the FDA regarding its (Z)-endoxifen program for metastatic breast cancer.

Atossa Therapeutics, Inc. does not experience traditional demand seasonality for commercialized products or services, as it currently generates no revenue from product sales. The company's value and "demand" from an investment perspective are primarily driven by the progress and outcomes of its clinical trials, regulatory milestones, and scientific advancements in its drug development pipeline.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology, particularly breast cancer. Their lead drug candidate is oral (Z)-endoxifen, being developed for breast cancer prevention and treatment. Atossa was also developing COVID-19 drugs, including AT-H201 and AT-301.

Atossa Therapeutics, Inc. is headquartered in Seattle, Washington, United States. Its operations primarily involve research and development and clinical trials, which may have a broader, potentially global reach, though its core corporate presence is U.S.-based.

Atossa Therapeutics has maintained a positive brand reputation over the past year due to scientific advancements and regulatory progress. Winning the 2025 Clinical Trials Arena Research and Development Award and the FDA granting Rare Pediatric Disease designation to (Z)-endoxifen for Duchenne Muscular Dystrophy positively affected its reputation. Receiving positive feedback from the FDA regarding its (Z)-endoxifen program for metastatic breast cancer also contributed to its positive brand image.

The ownership structure of Atossa Therapeutics consists of institutional, insider, and public/individual investors. Approximately 12.75% of the company's stock is owned by Institutional Investors, 3.41% by Insiders, and 83.84% by Public Companies and Individual Investors. Major institutional shareholders include Vanguard Group Inc. and Ameriprise Financial Inc. Insiders increased their holdings from 0.73% to 4.36% in January 2026.